Item 7.01 Regulation FD Disclosure.
Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various times between December 1, 2022 and December 31, 2022. During these meetings, the Company intends to address its prospects and performance. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company’s website at www.humana.com.
Full Year 2023 Individual Medicare Advantage Enrollment Projection
Based on annual enrollment period (AEP) activity to date, the Company is increasing its net membership growth estimate for its individual Medicare Advantage products for the year ended December 31, 2023 (“FY 2023”) to ‘at least 500,000’ members from the previous guidance range of 325,000 to 400,000 members. The revised membership estimate represents expected net membership gains of at least 10.9 percent over the projected year ending December 31, 2022 membership, above the Company’s expectation of high single-digit industry growth.
The upward revision is primarily attributable to higher than expected sales experienced to date. Retention is also anticipated to be modestly favorable. Management will continue to evaluate emerging membership trends and provide additional updates as necessary.
Full Year 2023 Adjusted EPS Commentary
For FY 2023, the Company intends to reiterate its commitment to grow 2023 Adjusted earnings per common share (“Adjusted EPS”) within its targeted long-term range of 11-15 percent from its expected 2022 Adjusted EPS of $25.00. As communicated on the Company’s third quarter 2022 earnings call on November 2, 2022, it expects the consensus estimate of approximately $27.90 (as of November 2, 2022) to be in line with its initial Adjusted EPS guidance.
The increased 2023 individual Medicare Advantage membership projection is not expected to have a material impact on FY2023 Adjusted EPS expectations.
Full Year 2022 Adjusted EPS Guidance
For the year ending December 31, 2022 (“FY 2022”) the Company intends to reaffirm its guidance of approximately $23.27 in diluted earnings per common share (“EPS”) or approximately $25.00 in Adjusted EPS. This guidance is consistent with the guidance issued in Humana’s press release dated November 2, 2022.
The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company’s ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company’s business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:
| | | | | |
Diluted earnings per common share | FY 2022 Guidance |
GAAP | approximately $23.27 |
Amortization of identifiable intangibles | 0.48 |
Put/call valuation adjustments associated with Company's non-consolidating minority interest investments | (0.10) | |
Transaction and integration costs | 0.62 | |
Change in fair market value of publicly-traded equity securities | 0.72 | |
Charges associated with productivity initiatives related to the previously disclosed $1 billion value creation plan | 1.73 | |
Net gain on the sale of KAH Hospice | (1.72) | |
Adjusted (non-GAAP) – FY 2022 projected | approximately $25.00 |
Cautionary Statement
This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, generally including the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions that are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the Company’s SEC filings.